When Non-Hodgkin’s lymphoma doesn’t respond to initial treatment or returns after a period of improvement, it creates a challenging situation that requires careful management and consideration of new treatment approaches.

Understanding Refractory and Relapsed Non-Hodgkin’s Lymphoma

Non-Hodgkin’s lymphoma that doesn’t behave as expected during or after treatment falls into two important categories that doctors use to guide care decisions. The term refractory lymphoma describes a situation where the cancer doesn’t respond to treatment at all, meaning the cancer cells continue to grow despite therapy, or when any response to treatment doesn’t last very long. This can be particularly frustrating for patients who begin treatment with hope, only to find that the lymphoma remains active.^[1]

The term relapsed lymphoma refers to disease that comes back after a period when there were no signs of cancer. Doctors typically use this term when lymphoma returns after a patient has achieved remission (meaning no evidence of lymphoma shows up on tests and scans) that lasts for at least six months following treatment. Relapse can happen because small numbers of lymphoma cells may have remained in the body after treatment, even though they weren’t detectable with available tests.^[1]

While most patients with aggressive non-Hodgkin lymphoma will be cured with initial treatment using a combination of chemotherapy and targeted therapy, unfortunately most patients whose disease comes back or doesn’t respond will not be cured and face significant health challenges. In these cases, continuing with the same conventional chemotherapy typically doesn’t provide benefit and can actually contribute to significant side effects and reduced quality of life.^[2]

How Relapse is Detected

After completing initial treatment for Non-Hodgkin’s lymphoma, patients have regular follow-up appointments to monitor their health and watch for any problems. These appointments serve as important checkpoints where doctors examine patients and ask about specific symptoms they should watch for. During these visits, healthcare providers look for signs that the lymphoma might have returned.^[8]

If a doctor suspects that lymphoma has come back, they will arrange additional testing. This might include blood tests to check for abnormalities in blood cell counts or other markers, imaging scans such as CT or PET scans to look for enlarged lymph nodes or other signs of disease, and potentially another lymph node biopsy to examine tissue under a microscope. The combination of these tests helps doctors determine whether lymphoma has truly relapsed and, if so, how much disease is present and where it’s located.^[8]

Patients should be aware of symptoms that might signal a return of lymphoma. These can include swollen lymph nodes that appear in the neck, armpits, or groin, significant weight loss without trying, fevers that persist or recur, night sweats so intense they soak through bedsheets, and persistent fatigue or weakness that doesn’t improve with rest. While these symptoms don’t always mean lymphoma has returned, they should prompt a conversation with your healthcare team.^[8]

What Affects Treatment Choices for Refractory or Relapsed Disease

When Non-Hodgkin’s lymphoma comes back or doesn’t respond to initial treatment, several factors influence what happens next. The approach to further treatment depends heavily on the grade of the lymphoma, meaning whether it’s a slow-growing (low-grade or indolent) type or a fast-growing (high-grade or aggressive) type. The specific subtype of Non-Hodgkin’s lymphoma also matters, as different subtypes respond differently to various treatments.^[8]

The treatments a patient has already received play a crucial role in determining next steps. Doctors carefully review what therapies were tried before, what worked, what didn’t, and why certain treatments may have failed. This information guides decisions about whether to try stronger doses of similar medications, switch to completely different approaches, or consider more intensive options. A patient’s overall health and fitness level also factor into these decisions, as some treatments place greater demands on the body than others.^[2]

Age is another consideration, as many treatments for lymphoma can strain the body, and older patients or those with other health conditions may not tolerate certain intensive therapies as well as younger, healthier individuals. That said, age alone shouldn’t prevent someone from receiving appropriate treatment, and many older adults do very well with carefully selected regimens.^[3]

Treatment Options for Relapsed or Refractory Non-Hodgkin’s Lymphoma

The good news is that multiple treatment options exist for people whose Non-Hodgkin’s lymphoma has relapsed or proven refractory. The treatments available for these situations are often the same ones used when lymphoma is first diagnosed, but they may be used in different combinations, at different doses, or in different sequences. In some cases, the treatment may be more intensive than what was given initially.^[8]

For patients with relapsed or refractory disease, doctors may recommend various chemotherapy regimens. These are combinations of cancer-killing drugs that work in different ways to attack lymphoma cells. Second-line chemotherapy regimens commonly used include combinations with medications like ifosfamide, carboplatin, and etoposide (known as ICE), or combinations including dexamethasone, cisplatin, and cytarabine (called DHAP). There are also gemcitabine-based therapies and other combinations that have shown effectiveness in treating disease that has returned.^[4]

High-dose chemotherapy followed by stem cell transplantation represents an important option for many patients with relapsed or refractory diffuse large B-cell lymphoma, one of the most common aggressive forms of Non-Hodgkin’s lymphoma. This approach uses very high doses of chemotherapy to destroy as many lymphoma cells as possible, including those that might be resistant to standard doses. Because this intensive chemotherapy also destroys the bone marrow (where blood cells are made), patients need a transplant to replace their damaged bone marrow with healthy stem cells.^[4]

Most patients undergoing stem cell transplantation for lymphoma have what’s called an autologous transplant, where they receive their own stem cells that were collected and stored before the high-dose chemotherapy. Less commonly, patients may have an allogeneic transplant, where they receive stem cells from a donor. The type of transplant recommended depends on individual circumstances, including the patient’s age, overall health, and the characteristics of their lymphoma.^[4]

Targeted therapies offer another avenue of treatment. These medications specifically target certain molecules or pathways that lymphoma cells need to grow and survive. Examples include bendamustine combined with rituximab, lenalidomide combined with rituximab, and newer agents like polatuzumab vedotin, selinexor, and tafasitamab. These drugs often work differently than traditional chemotherapy and may be effective even when other treatments have failed.^[4]

Radiotherapy may be used in some situations, particularly when lymphoma has returned in a specific, localized area of the body. This treatment uses high-energy rays to kill cancer cells in the targeted region. It’s typically given in short daily sessions over several weeks and can be effective for controlling disease in specific locations.^[3]

Advanced Immunotherapy Approaches

One of the most promising developments in treating relapsed or refractory Non-Hodgkin’s lymphoma involves immunotherapy, treatments that help the body’s own immune system recognize and attack cancer cells. A particularly innovative form called chimeric antigen receptor T-cell therapy, or CAR T-cell therapy, has shown remarkable potential for some patients whose lymphoma has not responded to other treatments.^[4]

CAR T-cell therapy works by collecting a patient’s own immune cells called T-cells, genetically engineering them in a laboratory to recognize and attack lymphoma cells, then infusing these modified cells back into the patient’s body. The engineered T-cells can seek out and destroy cancer cells throughout the body. Several CAR T-cell therapies have been approved for relapsed or refractory Non-Hodgkin’s lymphoma, including axicabtagene ciloleucel (Yescarta), lisocabtagene maraleucel (Breyanzi), and tisagenlecleucel (Kymriah). These treatments have provided new hope for patients who had run out of other options, and in some cases have achieved long-lasting remissions.^[4]

Newer immunotherapy approaches include bispecific antibodies, which are medications designed to connect T-cells with lymphoma cells, helping the immune system target the cancer more effectively. Examples include epcoritamab (Epkinly) and glofitamab (Columvi), which represent additional options for patients with disease that has relapsed or proven refractory to other treatments.^[4]

Watch and Wait: When Immediate Treatment Isn’t Necessary

Not all patients with relapsed Non-Hodgkin’s lymphoma need immediate treatment. For those with low-grade (slow-growing) lymphoma who feel well and aren’t experiencing troublesome symptoms, doctors may recommend what’s called “watch and wait” or active monitoring. This approach recognizes that some people with indolent lymphoma can go for many years before developing symptoms that require treatment, and starting therapy immediately may not provide additional benefit while potentially causing unnecessary side effects.^[3]

During a watch-and-wait period, patients have regular check-ups where their doctor monitors the lymphoma through physical examinations and, when needed, blood tests or scans. Patients are encouraged to contact their healthcare team at any time if they notice their symptoms worsening or develop new concerning signs. This approach allows patients to maintain quality of life without the burden of treatment until it becomes truly necessary.^[3]

Goals of Treatment for Relapsed or Refractory Disease

Understanding what treatment aims to achieve is important for patients facing relapsed or refractory Non-Hodgkin’s lymphoma. In some cases, particularly with certain types of aggressive lymphoma or when patients are otherwise healthy and able to tolerate intensive therapy, the goal may still be to cure the disease. This is especially true for patients who are candidates for high-dose chemotherapy with stem cell transplantation or newer treatments like CAR T-cell therapy.^[8]

Even when cure may not be possible, treatment can often control the lymphoma effectively for long periods. Many patients with relapsed Non-Hodgkin’s lymphoma experience long periods when they feel well and the disease is under control, alternating with times when they need treatment. Some people don’t relapse again for many years, allowing them to maintain good quality of life for extended periods. The pattern of lymphoma behavior can be unpredictable, with some patients experiencing long remissions between relapses.^[8]

Treatment goals are individualized based on each patient’s situation, including the type and grade of their lymphoma, their overall health, previous treatments, and personal preferences. Open conversations with the healthcare team about treatment goals, expected outcomes, and potential side effects help ensure that the chosen approach aligns with what matters most to the patient.^[2]

Clinical Trials and Emerging Therapies

Clinical trials represent an important option for many patients with relapsed or refractory Non-Hodgkin’s lymphoma. These research studies test new treatments or new combinations of existing treatments to determine if they’re safe and effective. Participating in a clinical trial may provide access to cutting-edge therapies that aren’t yet widely available, including novel medications, new immunotherapy approaches, or innovative treatment strategies.^[2]

Fortunately, many new therapies are currently available or under investigation for patients with relapsed or refractory Non-Hodgkin’s lymphoma. These range from oral medications called tyrosine kinase inhibitors that target multiple pathways within cancer cells, to sophisticated cellular therapies that harness the patient’s immune system to fight disease. Many agents that show modest effectiveness when used alone can be safely combined with other novel or conventional therapies to improve response rates and how long those responses last.^[2]

Before enrolling in a clinical trial, patients should understand what the study involves, including the treatment approach being tested, potential risks and benefits, how often they’ll need to visit the treatment center, and what monitoring will be required. Healthcare teams can help patients understand whether a particular clinical trial might be appropriate for their situation and how it compares to standard treatment options.^[3]

Managing Side Effects and Quality of Life

Treatment for relapsed or refractory Non-Hodgkin’s lymphoma can cause side effects, some of which may be similar to those experienced during initial treatment, while others may be new. Chemotherapy can affect the bone marrow, potentially causing fatigue, breathlessness, increased vulnerability to infections, and easy bleeding or bruising. When these problems occur, treatment may need to be paused to allow the body to recover and produce more healthy blood cells. Medications called growth factors can help stimulate blood cell production.^[3]

Other common side effects of chemotherapy include nausea and vomiting, diarrhea, loss of appetite, mouth ulcers, tiredness, skin rashes, and hair loss. Most side effects should pass once treatment is finished, and there are often supportive medications or strategies available to help manage them. Patients should tell their healthcare team if side effects become particularly troublesome, as interventions are often available to provide relief.^[3]

Newer treatments like CAR T-cell therapy can have their own unique side effects that require careful monitoring. Healthcare teams experienced with these therapies know how to watch for and manage potential complications. Radiotherapy can cause side effects specific to the area being treated, such as skin irritation, fatigue, and symptoms related to the body part receiving radiation.^[3]

Looking Forward

While facing relapsed or refractory Non-Hodgkin’s lymphoma is undoubtedly challenging, the landscape of available treatments continues to expand. The development of novel therapies, particularly immunotherapies like CAR T-cell therapy, has transformed outcomes for many patients who previously had few options. Research continues to uncover new treatment approaches and identify which patients are most likely to benefit from specific therapies.^[2]

People with relapsed or refractory Non-Hodgkin’s lymphoma are living longer than ever before, thanks to advances in treatment. Some patients achieve long-term remissions or even cures with newer therapies, while others are able to manage their disease effectively for extended periods. The key is working closely with an experienced healthcare team to identify the most appropriate treatment strategy based on individual circumstances, preferences, and goals.^[12]